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Introduction 
Absolute erythrocytosis is characterized by persistently raised haemoglobin (Hb) and hematocrit 
(Ht) levels. The most studied form of absolute erythrocytosis is Polycythemia Vera (PV), a primary 
neoplastic disease characterized by the presence of JAK2 mutations, risk of vascular complications 
and of evolution to myelofibrosis or acute leukemia. Secondary erythrocytosis is represented by 
rare congenital diseases (such as oxygen sensing pathway genes mutation), acquired forms or 
idiopathic erythrocytosis (IE). IE can be divided into two main groups. The first group consists of 
those with a low EPO level suggesting an unidentified molecular defect possibly involving 
components of the EPO signal transduction pathway. The second group is those with 
inappropriately normal or raised EPO level which suggests a secondary unidentified cause possibly 
with aberrations in the oxygen sensing pathway (McMullin, 2012). These patients are rarely 
observed in clinical practice, and little is known regarding their clinical characteristics, natural 
history and best management (Randi et al, 2015).  
Hereditary Haemochromatosis (HH) is a disease which leads to an iron balance impairment 
characterized by raised serum ferritin and resulting iron overload in several organs. There are four 
types of HH, classified by the genetic abnormality underlying the disease. The most frequent is 
Type 1, associated with HFE gene mutations on chromosome 6 (Yun & Vincelette, 2015): the most 
common HFE mutations observed are H63D and C282Y which allele frequencies in Europe are 
respectively 13.6% and 3.8% (Merryweather et al, 1997). The HFE gene encodes for a protein 
involved in the regulation of hepcidin and hence iron homeostasis (Gao et al, 2008). Increased iron 
bioavailability which results from the defects of molecules involved in iron balance could lead to 
increased erythropoiesis and hence erythrocytosis (Camaschella, 2013), with increased levels of 
ferritin often observed in IE. Postulating that a possible underlying cause for erythrocytosis could 
be impairment in iron metabolism, we searched for the presence of HFE mutations in IE. 
Patients, materials and methods 
 
We studied 56 patients with IE: 18 were enrolled in Padua (Italy) and 38 in Belfast (UK). All the 
patients had normal serum EPO level and none of them carried JAK2V617F or JAK2 exon 12 
mutations. Congenital erythrocytosis were excluded for the absence of a familial increase of red 
cells and by the negative research of EPO-R, VHL, PHD2, HIF-1α mutations. None of the patients 
had an overt hemochromatosis or a previous documented HFE mutation.  Clinical and laboratory 
data of the patients are shown in Table I. 
The procedures followed were in accordance with the Declaration of Helsinki and all patients gave 
informed written consent.  We performed DNA extraction using Roche® “MagNa Pure Compact 
System” and the analysis of HFE genotypes using Lightcycler 480 by Roche®.  
The frequency of HFE mutations among IE and the frequency in general population of UK and Italy 
(Merryweather et al, 1997) were compared using a Fisher’s exact test. Means and standard 
deviations were compared with T test. 
 
Results 
The patients were mostly males in both the groups with a higher frequency in the Italian cohort. 
Patients in the UK cohort were significantly younger at diagnosis, had significantly higher 
haemoglobin (Hb), haematocrit (Ht), mean cell volume (MCV). Epo levels were low in both the 
groups, and lower in UK compared to Italian patients. Mean serum ferritin levels were higher in 
Italian than in UK patients with a significant difference (p=0.02). 
Nineteen patients (33.9%) had high ferritin at diagnosis. In total, 25 patients (7 = 38.8% Italian and 
18 = 47.4% from UK) were found with HFE mutations, representing 44.6% of our total IE 
population. Within our mutated patients, 12 (48%) had high ferritin levels. The number of patients 
with high ferritin levels is not different (p=0.054) among HFE mutated and wild type patients 
(Table II). 
Two and 4 patients from UK were homozygous and heterozygous respectively for C282Y mutation; 
1 Italian and 1 UK IE were homozygous H63D and 5 Italian and 9 UK were heterozygous H63D. In 
one Italian patient compound C282Y/H63D heterozygosity was found. Finally, two UK patients 
carried the S65C mutation (1 heterozygous and 1 compound S65C/C282Y). 
 
Discussion 
 
Still now a number of patients with high haemoglobin levels are considered affected by “idiopathic 
erythrocytosis”, which means that the etiology of their condition is not understood. Even if it has 
been evaluated that about 70% of all erythrocytosis are IE (Bento et al, 2015), this condition is 
poorly studied and no proper diagnosis can be made. 
 
In the past, a correlation among erythrocytosis and HH has been suspected (Raphael et al, 1979). 
HH patients do not always have increased ferritin levels and the presence of high ferritin is not 
always related to the different HFE genotypes (Olynyk et al, 1999), even if C282Y mutation seems 
to display more often an important iron overload (Burke et al, 2000). 
 
Our data show that a relevant number of patients with IE carry HFE mutations in two distinct 
European cohorts. This observation is limited by the small number of patients, however, 
comparing the incidence of HFE mutations in IE and its frequency in general population 
(Merryweather et al, 1997), we found that IE patients carry H63D or C282Y more often (p=0.048). 
This represents a novel finding not previously reported.   
 
High ferritin levels were observed in half of our mutated and in one third of wild-type patients. 
The difference was not significant even if there is a trend towards a higher frequency of high 
ferritin in mutated patients. Probably, a statistical difference could become evident exploring a 
higher number of patients.  
Unfortunately, transferrin saturation, that is now considered an important criterion for 
hemochromatosis diagnosis (Bacon et al, 2011), was not collected in most patients at the time of 
diagnosis together with ferritin values. Many of the patients included in this study have undergone 
phlebotomies (about 60% of the patients) for the treatment of erythrocytosis, and for this reason 
we considered to be useless a later transferrin saturation evaluation. 
 
Not surprisingly, HFE mutations were more frequent in UK cohort, and there is a particular 
frequency of C282Y mutation: this is compatible with the finding of the founder effect in Celtic 
population (Lucotte & Mercier, 2000). Interestingly, we encountered in one Italian patient the 
presence of a C282Y mutated allele (compound C282Y/H63D heterozygosity). This genotype is a 
rare finding in southern-Europe (Merryweather et al, 1997; Cassanelli et al, 2001). In 2 patients, 
both from UK, we found a S65C allele: in one case it was compound with C282Y and in one case it 
was heterozygous. The allele frequency of S65C is rare and in white population is estimated to be 
1.6% (Beutler et al, 2000).  
 
The mechanism of IE in patients with HFE mutations has to be elucidated. While an iron overload 
can be claimed in patients with raised ferritin levels, the relationship between IE and HFE when 
ferritin is within normal levels is not yet understood. HFE mutated protein limits hepcidin 
expression and increases transferrin-bound iron uptake by erythroid cells. 
It has been demonstrated that HFE C282Y homozygotes display increased plasma iron turnover 
and increased erythropoiesis suggesting that HFE mutations alter the supply of iron to the 
erythroid tissues (Feeney et al, 2005). In this work, we searched for a possible new cause for 
erythrocytosis, and our findings suggest a possible relation between the presence of HFE 
mutations and erythrocytosis, although hepcidin, ferroportin, erythroferrone and other molecules 
involved in iron regulation have to be evaluated in large cohort of IE patients to clarify the physio-
pathological relation between HH and erythrocytosis. 
 Table I: Main clinical and laboratory data of patients with erythrocytosis. 
 
 
Table II: Different HFE genotypes and their distribution among patients with high or normal ferritin 
levels 
 
 
 
 
 
 
 
 
 
 
 ITALIAN COHORT UK COHORT TOTAL 
N° 18 38 56 
Males (%) 17 (94.4) 27 (71.0) 44 (78.6) 
Mean Age at diagnosis ± SD (years)  54 ± 12 44 ± 14 47 ± 14 
Mean Hb at diagnosis ± SD (g/dL) 17.8 ± 1.0 19.6 ± 1.9 19.0 ± 1.8 
Mean Ht at diagnosis ± SD (%) 52 ± 3 57 ± 7 55 ± 6 
Mean WBC at diagnosis ± SD 8.0 ± 2.5 8.3 ± 2.2 8.1 ± 2.3 
Mean MCV at diagnosis ± SD (x109/l) 88 ± 5 96 ± 7 94 ± 7 
Mean Plts at diagnosis ± SD  (x109/l) 228 ± 53 220 ± 71 223 ± 65 
Mean EPO at diagnosis ± SD (UI) 10.0 ± 5.7 5.9 ± 2.6 7.0 ± 4.1 
Mean Ferritin at diagnosis ± SD (ng/ml) 330.5 ± 239.2 162.9 ± 146.1 227.7 ± 202.5 
 High ferritin Normal ferritin 
N° of patients 19 37 
H63D/H63D (%) 1 (5.3) 1 (2.7) 
H63D/wt (%) 8 (42.1) 6 (16.2) 
C282Y/C282Y (%) 1 (5.3) 1 (2.7) 
C282Y/wt 1 (5.3) 3 (8.1) 
H63D/C282Y 1 (5.3) 0 
C282Y/S65C 0 1 (2.7) 
S65C/wt 0 1 (2.7) 
Wt/wt 7 (36.8) 24 (64.9) 
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